Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Nafamostat Mesylate Versus Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy in Sepsis-Associated Acute Kidney Injury

NCT07518303 is registered in ClinicalTrials.gov with Jianfeng Xie as lead sponsor.

NCT NCT07518303
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07518303 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Nafamostat Mesylate Versus Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy in Sepsis-Associated Acute Kidney Injury
Lead sponsor
Jianfeng Xie
Phase
Phase 4
Overall status
Not yet recruiting
Start date
June 10, 2026
Completion date
December 10, 2028
Enrollment
1,162 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute kidney injury, continuous renal replacement therapy (crrt), sepsis